Fumaric acid esters in severe ulcerative necrobiosis lipoidica: A case report and evaluation of current therapies

Acta Dermato-Venereologica

Volumn 90, Issue 1, 2010, Pages 104-106

  Eberle, Franziska C ^a   Ghoreschi, Kamran ^b   Hertl, Michael ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; CALCINEURIN INHIBITOR; CYCLOSPORIN; FUMADERM; FUMARIC ACID ETHYL ESTER; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PENTOXIFYLLINE; PREDNISOLONE; PSORALEN; TACROLIMUS; THALIDOMIDE;

ADULT; CAPSULE ENDOSCOPE; CASE REPORT; CLINICAL EVALUATION; DISEASE SEVERITY; DRUG MEGADOSE; DYSESTHESIA; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LETTER; LOW DRUG DOSE; NECROBIOSIS LIPOIDICA; PAIN; PRIORITY JOURNAL; PSORIASIS; PUVA; SKIN BIOPSY; SKIN ULCER; TREATMENT OUTCOME; ULCERATIVE NECROBIOSIS LIPOIDICA;

ADULT; BIOPSY; DERMATOLOGIC AGENTS; FEMALE; FUMARATES; GLUCOCORTICOIDS; HUMANS; NECROBIOSIS LIPOIDICA; PHOTOTHERAPY; SEVERITY OF ILLNESS INDEX; SKIN; SKIN ULCER; TREATMENT OUTCOME;

EID: 76349094277     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0757     Document Type: Letter

References (15)

1. Kreuter A, Knierim C, Stucker M, Pawlak F, Rotterdam S, Altmeyer P, et al. Fumaric acid esters in necrobiosis lipoidica: results of a prospective noncontrolled study. Br J Dermatol 2005; 153: 802-807.
2. Breuer K, Gutzmer R, Volker B, Kapp A, Werfel T. Therapy of noninfectious granulomatous skin diseases with fumaric acid esters. Br J Dermatol 2005; 152: 1290-1295.
3. De Rie MA, Sommer A, Hoekzema R, Neumann HA. Treatment of necrobiosis lipoidica with topical psoralen plus ultraviolet A. Br J Dermatol 2002; 147: 743-747.
4. Beattie PE, Dawe RS, Ibbotson SH, Ferguson J. UVA 1 phototherapy for treatment of necrobiosis lipoidica. Clin Exp Dermatol 2006; 31: 235-238.
5. Berking C, Hegyi J, Arenberger P, Ruzicka T, Jemec GB. Photodynamic therapy of necrobiosis lipoidica - a multicenter study of 18 patients. Dermatology 2009; 218: 136-139.
6. Statham B, Finlay AY, Marks R. A randomized double blind comparison of an aspirin dipyridamole combination versus a placebo in the treatment of necrobiosis lipoidica. Acta Derm Venereol 1981; 61: 270-271.
7. Noz KC, Korstanje MJ, Vermeer BJ. Ulcerating necrobiosis lipoidica effectively treated with pentoxifylline. Clin Exp Dermatol 1993; 18: 78-79.
8. Petzelbauer P, Wolff K, Tappeiner G. Necrobiosis lipoidica: treatment with systemic corticosteroids. Br J Dermatol 1992; 126: 542-545.
9. Handfield-Jones S, Jones S, Peachey R. High dose nicotinamide in the treatment of necrobiosis lipoidica. Br J Dermatol 1988; 118: 693-696.
10. Durupt F, Dalle S, Debarbieux S, Balme B, Ronger S, Thomas L. Successful treatment of necrobiosis lipoidica with antimalarial agents. Arch Dermatol 2008; 144: 118-119.
11. Smith K. Ulcerating necrobiosis lipoidica resolving in response to cyclosporine-A. Dermatol Online J 1997; 3: 2.
12. Ghoreschi K, Rocken M. Immune deviation strategies in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy 02004; 3: 193-198.
13. Loewe R, Holnthoner W, Groger M, Pillinger M, Gruber F, Mechtcheriakova D, et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 2002; 168: 4781-4787.
14. Vandermeeren M, Janssens S, Borgers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 1997; 234: 19-23.
15. Litjens NH, Rademaker M, Ravensbergen B, Rea D, van der Plas MJ, Thio B, et al. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur J Immunol 2004; 34: 565-575.